Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability

Cell Rep Med. 2023 Aug 15;4(8):101153. doi: 10.1016/j.xcrm.2023.101153.

Abstract

Azathioprine (AZA) therapy failure, though not the primary cause, contributes to disease relapse and progression in inflammatory bowel disease (IBD). However, the role of gut microbiota in AZA therapy failure remains poorly understood. We found a high prevalence of Blautia wexlerae in patients with IBD with AZA therapy failure, associated with shorter disease flare survival time. Colonization of B. wexlerae increased inflammatory macrophages and compromised AZA's therapeutic efficacy in mice with intestinal colitis. B. wexlerae colonization reduced 6-mercaptopurine (6-MP) bioavailability by enhancing selenium-dependent xanthine dehydrogenase (sd-XDH) activity. The enzyme sd-XDH converts 6-MP into its inactive metabolite, 6-thioxanthine (6-TX), thereby impairing its ability to inhibit inflammation in mice. Supplementation with Bacillus (B.) subtilis enriched in hypoxanthine phosphoribosyltransferase (HPRT) effectively mitigated B. wexlerae-induced AZA treatment failure in mice with intestinal colitis. These findings emphasize the need for tailored management strategies based on B. wexlerae levels in patients with IBD.

Keywords: 6-mercaptopurine; azathioprine therapy failure; biotransformation; inflammatory bowel disease; microbiome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azathioprine / therapeutic use
  • Bacteria
  • Biological Availability
  • Colitis* / chemically induced
  • Colitis* / drug therapy
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases* / drug therapy
  • Mercaptopurine / therapeutic use
  • Mice

Substances

  • Mercaptopurine
  • Azathioprine
  • Immunosuppressive Agents